Cortexyme, Inc. - Common Stock (NQ:CRTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	1.890 (7)
Ask (Size)	1.990 (2)
Prev. Close	1.950
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	36,382,989
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Stocks That Hit 52-Week Lows On Thursday ↗

July 28, 2022

On Thursday, 108 companies set new 52-week lows.

Via Benzinga

Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves ↗

May 03, 2022

Via Benzinga

Performance

More News

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 27, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

July 27, 2022

Via Benzinga

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

July 27, 2022

From Cortexyme, Inc.

Via Business Wire

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

July 27, 2022

From Cortexyme, Inc.

Via Business Wire

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

June 21, 2022

From Cortexyme, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

July 25, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

June 24, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 16, 2022

Via Benzinga

Cortexyme Appoints June Bray to its Board of Directors

June 13, 2022

From Cortexyme, Inc.

Via Business Wire

69 Biggest Movers From Friday ↗

June 06, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

June 01, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 31, 2022

Via Benzinga

Cortexyme Appoints Dr. Philip Low to Its Board of Directors

May 20, 2022

From Cortexyme, Inc.

Via Business Wire

Cortexyme Successfully Completes Acquisition of Novosteo

May 20, 2022

From Cortexyme, Inc.

Via Business Wire

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

May 12, 2022

From Cortexyme, Inc.

Via Business Wire

103 Biggest Movers From Yesterday ↗

May 11, 2022

Via Benzinga

77 Stocks Moving In Tuesday's Mid-Day Session ↗

May 10, 2022

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Via Benzinga

Cortexyme Announces Agreement to Acquire Novosteo

May 10, 2022

From Cortexyme, Inc.

Via Business Wire

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Via Benzinga

NASDAQ:CRTX Investor Alert: Investigation over Potential Wrongdoing at Cortexyme, Inc. ↗

April 29, 2022

Via SBWire

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX

April 05, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population

March 21, 2022

From Cortexyme, Inc.

Via Business Wire

Frequently Asked Questions

Is Cortexyme, Inc. - Common Stock publicly traded?

Yes, Cortexyme, Inc. - Common Stock is publicly traded.

What exchange does Cortexyme, Inc. - Common Stock trade on?

Cortexyme, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cortexyme, Inc. - Common Stock?

The ticker symbol for Cortexyme, Inc. - Common Stock is CRTX on the Nasdaq Stock Market

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.